2026-10-25
Pediatrix Medical Group, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 29,813 +0.55%
S&P 7,744 +0.28%
GOLD $4,077 +0.07%
BTC $81,598 +0.98%
VIX 16.87 −3.71%
latest tape · as of 20:04 UTC
The Screen · Healthcare · Medical Care Facilities
Pediatrix Medical Group, Inc.
MD · the NYSE · USD · Market cap $2.3B · 4,280 employees
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States.
Not yet scored29.29 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 5 days ago
Screened 2026-10-23 · the tape above runs as of 20:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price29.29 USD at the 23 Oct 2026 close
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.02)
- Last reviewed23 Oct 2026 (5 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 29.29 against the desk's fair-value range, base estimate 28.00, over the last year.
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.02, read 2026-10-27
- Ethical screen not yet scored
Price29.29 USD
Fair value28.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-14Read Accumulation26.64+9.9% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown25.77+13.7% to today Accumulation gives way to Markdown
2026-09-05Read Accumulation26.80+9.3% to today ✓Distribution gives way to Accumulation after a 10% rise in 9 weeks
2026-07-02Read Distribution24.30+20.5% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its accumulation label.
Pediatrix Medical Group, Inc. holds its Accumulation at $29.29. Consolidating, no directional conviction, held for 52 days.
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 52 days |
| Price at the screen | $29.29 |
| Valuation | 13.44 trailing · 11.51 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.61 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 28.25% | Below 33% | Interest-bearing debt is just 28.2% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 5.54% | Below 33% | Cash held in interest-bearing accounts and securities is 5.5% of assets, under the one-third limit. | Pass |
| Receivables | 26.92% | Below 49% | Money owed to the company is 26.9% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Pediatrix Medical Group, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Pediatrix Medical Group, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 28%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. The price runs 0.4% above the base estimate.
Third-party analyst targets: 6 covering, consensus Hold. The average target sits −4% from the screen price.
Reading the gap · Our model and the Street both land near the screened price: fairly valued, with no strong edge either way.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsPaediatric care provider offers almost no margin
Every day fragile newborns depend on specialist teams inside US hospitals, yet the company delivering that care trades barely below our fair value. With revenue expanding only 4% and a slim 7% gap to our $28 mark, there is little reason to step in when the current price already sits at $26.13. Analysts see the same picture, clustering their targets right around today's level.
The business clears our ethical screen and earns a solid 21% ROE with a forward multiple of 11.1x, but those strengths do not create an opportunity. Low single-digit growth and an unknown moat leave the shares looking fairly valued rather than overlooked. A 9% profit margin offers stability, yet nothing here suggests the market has mispriced the risks.
Currency or regulatory shocks in healthcare could quickly close the tiny gap that exists. We therefore pass. Analysis, not advice.
| Forward P/E | 11.5xexpensive even after accounting for its growth |
| Trailing P/E | 13.4xreasonably valued |
| EPS, trailing | 2.09 |
| EPS, forward | 2.44 |
| Revenue growth | +4.0%slow but positive growth |
| Profit margin | 9.0%thin but positive margins |
| Return on equity | 20.4%an exceptional return on shareholder capital |
| FCF yield | 7.04% |
| Debt to equity | 0.70moderate, manageable leverage |
| Current ratio | 1.32adequate liquidity, worth monitoring |
| Beta | 0.61steadier than the market |
| Short interest, float | 0.08% |
| 52-week range | 16.82 - 28.29 |
| Market cap | $2.3B |
| Employees | 4,280 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeMD trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-28
Accumulation $28.10
+0.0% Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it none, with a mean price target of $23. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27
Accumulation $28.10
+0.0% Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it none, with a mean price target of $23. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26
Accumulation $28.10
+0.0% Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it none, with a mean price target of $23. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25
Accumulation $28.10
+0.0% Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it none, with a mean price target of $23. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24
Accumulation $28.10
+0.0% Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it none, with a mean price target of $23. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23
Accumulation $28.10
+0.0% Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it none, with a mean price target of $23. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22
Accumulation $28.10
+1.2% Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it none, with a mean price target of $23. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21
Accumulation $27.76
+4.2% Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it none, with a mean price target of $23.
2026-10-14
Accumulation · changed $26.64
+3.4% Entry 7
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it none, with a mean price target of $23.
2026-10-02
Markdown · changed $25.77
-3.8% Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it none, with a mean price target of $23.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- 1 value stock worth investigating and 2 we question Yahoo Finance · 5d ago
- Pediatrix Medical Group (MD) Stock Looks Undervalued Despite Its 154% Run Yahoo Finance · 5d ago
- Pediatrix Medical Group 2026 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 29, 2026 Yahoo Finance · 8d ago
- 3 Reasons MD is Risky and 1 Stock to Buy Instead Yahoo Finance · 14d ago
- 3 Unpopular Stocks with Questionable Fundamentals Yahoo Finance · 23d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
ADUSAddus HomeCare Corporation
BKDBrookdale Senior Living Inc.
GRDNGuardian Pharmacy Services, Inc.
SEMSelect Medical Holdings Corporation
SGRYSurgery Partners, Inc.
AVAHAveanna Healthcare Holdings Inc.
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-09-11 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-11 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-08-03 | Scott Peters | Democrat | sell | 50K–100K |
| 2026-08-03 | Scott Peters | Democrat | sell | 50K–100K |
| 2026-08-03 | Scott Peters | Democrat | sell | 50K–100K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $23.37 | +0.8% | · | $1,008 | +0.8% |
| 2 months | $21.45 | +9.8% | · | $1,098 | +9.8% |
| 3 months | $19.46 | +21.1% | · | $1,211 | +21.1% |
| 6 months | $22.11 | +6.6% | · | $1,066 | +6.6% |
| 1 year | $14.12 | +66.9% | · | $1,669 | +66.9% |
| 2 years | $6.91 | +241.0% | · | $3,410 | +241.0% |
| 3 years | $14.31 | +64.6% | · | $1,646 | +64.6% |
| 5 years | $32.26 | -27.0% | · | $730 | -27.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever MD does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.